CN106138947A - A kind of medicine treating heart kidney deficiency infantile enuresis and preparation method thereof - Google Patents
A kind of medicine treating heart kidney deficiency infantile enuresis and preparation method thereof Download PDFInfo
- Publication number
- CN106138947A CN106138947A CN201610680014.1A CN201610680014A CN106138947A CN 106138947 A CN106138947 A CN 106138947A CN 201610680014 A CN201610680014 A CN 201610680014A CN 106138947 A CN106138947 A CN 106138947A
- Authority
- CN
- China
- Prior art keywords
- fructus
- medicine
- kidney
- kidney deficiency
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention discloses a kind of medicine treating heart kidney deficiency infantile enuresis, it is prepared by following raw material: Carnis Canitis, Ootheca Mantidis, Fructus Tritici Levis, the Radix Paeoniae Alba, Semen sojae atricolor, Fructus Alpiniae Oxyphyllae, Fructus Schisandrae Chinensis.Medicine of the present invention, to adjust reinforcing the heart gas, training unit astringent or styptic treatment for spontaneous sweating as Therapeutic Principle, Carnis Canitis warming and invigorating the spleen and stomach, reinforcing the kidney and supporting YANG, arteries and veins of enriching blood in side, Fructus Alpiniae Oxyphyllae the kidney warming controlling nocturnal emission with astringent drugs reducing urination, both are monarch drug；Fructus Tritici Levis reinforcing the heart, only tired, Radix Paeoniae Alba blood-supplementing blood-nourishing, both be not only in harmonious proportion the scorching of monarch drug but also had coordinated monarch drug orderliness heart kidney is ministerial drug；Ootheca Mantidis supplementing the kidney to control the nocturnal, astringent therapy are only lost, and teata glycinis blood-enriching tranquillizing is adjuvant drug, Fructus Schisandrae Chinensis sour in the mouth, have receipts antiperspirant arresting seminal emission, priming return through effect.
Description
Technical field
The present invention relates to tcm field, particularly relate to a kind of medicine treating heart kidney deficiency infantile enuresis and
Preparation method.
Background technology
Bed-wetting is commonly called as wetting the bed, and is primary disease prognosis bona, if but do not heal for a long time, children's spirit can be made depressed, impact
Physically and mentally healthy.At present western medical treatment commonly uses imipramine hydrochloride, meclofenoxate, Anisodamine etc., short term efficacy still can, but have certain pair
Reaction, after drug withdrawal, relapse rate is the highest.
Infantile enuresis is Childhood a kind of common disease.Be 3 one full year of life above children's often in sleep urine from
A kind of disease that something lost, rear of waking up are felt, according to statistics, has bed-wetting phenomenon person to account for the 10-20% of child, accounts for 5% when 9 years old when 4 years old half,
And the person that still do not wets the bed for 15 years old only accounts for 2%.Primary disease is more common in boy, and boy is about 2:1 with the ratio of girl.6-7 year child morbidity
Rate is the highest.The infant of enuresis, majority can after the morbidity several years spontaneous recovery girl's spontaneous recovery rate higher, but also have part infant, as not
Through treatment, symptom can continue into adult life.Bed-wetting harm is huge, causes inconvenience in life to infant, the most serious
Affect infant health, mental health is grown up so that infant is self-doubt, easy anxiety, fears collective livelihood, and then has influence on him
School grade and intellectual development, severe patient even results in bigoted, violent tenet and suicidal tendency etc..Therefore, carry out in early days
Intervention has very important significance.
The Therapeutic Method of bed-wetting mainly has two kinds, i.e. behavior therapy and Drug therapy.Drug therapy divides treatment by Chinese herbs
And western medicine.Western medicine includes tricyclic antidepressant (imipramine hydrochloride), meclofenoxate and desmopressin acetate
(Desmopressin, DDAVP) etc., imipramine hydrochloride has been not used in bed-wetting treatment owing to having serious untoward reaction；
The correlational study data of meclofenoxate is less, and in-depth study of still needing inquires into its clinical effectiveness；Though DDAVP curative effect is relatively affirmed,
But expensive, do not accepted by extensive patients, after drug withdrawal, late result is the most unstable, and DDAVP is applied to simple urine
Bed patient, because some indication master is the most difficult, still has certain danger.Comparatively speaking Chinese medicine is treated at bed-wetting
On have its unique advantage place, there is the advantages such as instant effect, good effect, little, the low price of side effect, and use treatment by Chinese herbs
Bed-wetting late result is certainly.
Theory of Chinese medical science is thought, the morbidity of bed-wetting has void to have reality, based on void.Belong to void person, because natural endowment is not enough, dirty
Internal organs is weak, also because lacking of proper care after being ill, causes heart kidney two empty, lack of preservation of spirit instability of kidney QI, the urinary bladder being out of control.
Summary of the invention
The present invention provides the medicine for the treatment of heart kidney deficiency infantile enuresis, and this drug effect is fast, good effect, toxic and side effects
Little, it is prepared by following raw material: Carnis Canitis, Ootheca Mantidis, Fructus Tritici Levis, the Radix Paeoniae Alba, Semen sojae atricolor, Fructus Alpiniae Oxyphyllae, Fructus Schisandrae Chinensis.
Special instruction: it is the Canis familiaris L. of 10% that the Carnis Canitis mentioned in present specification is the dried water content of high temperature sterilize
Jerky.
The medicine of described treatment heart kidney deficiency infantile enuresis is the technical scheme is that by solving its technical problem
Thing, is made up of the crude drug of following weight: Carnis Canitis 6-18 part, Ootheca Mantidis 2-6 part, Fructus Tritici Levis 4-12 part, Radix Paeoniae Alba 2-6
Part, teata glycinis 4-12 part, Fructus Alpiniae Oxyphyllae 2-6 part, Fructus Schisandrae Chinensis 2-6 part.
The preferred technical solution of the present invention is, described medicine of the present invention is prepared by the raw material of following weight portion: Carnis Canitis 12 parts,
Ootheca Mantidis 4 parts, Fructus Tritici Levis 8 parts, the Radix Paeoniae Alba 4 parts, teata glycinis 8 parts, Fructus Alpiniae Oxyphyllae 4 parts, Fructus Schisandrae Chinensis 4 parts.
Present invention also offers the preparation method of described medicine, specifically include following steps: by the raw material of above-mentioned weight portion
Carnis Canitis, Ootheca Mantidis, Fructus Tritici Levis, the Radix Paeoniae Alba, teata glycinis, Fructus Alpiniae Oxyphyllae, after Fructus Schisandrae Chinensis is pulverized, add the water of 10 times amount of medical material gross weight,
After soaking 30 minutes, decoct 2 times, 60-90 minute for the first time, 30-60 minute for the second time, filter, and the filtrate after merging subtracts
When pressure is concentrated into 75 DEG C, its relative density is the thick paste of 1 .10-1 .15 and get final product.
Those skilled in the art directly can be used as medicine use on the basis of prepared active constituents of medicine of the present invention, or adds
On pharmaceutics, acceptable adjuvant is produced in conventional fashion into required preparation.As conventional tablet (dispersible tablet, effervescent can be made
Sheet, oral cavity disintegration tablet, buccal tablet, chewable tablet, effervescent tablet), capsule (hard capsule, soft capsule), granule, pill (drop pill
Agent), the oral drugs of the solid dosage form such as powder, it is also possible to make the liquid systems such as syrup, oral liquid, water preparation, mixture, decoction
The oral drugs of agent form.Therefore, in this pharmaceutical composition in addition to effective ingredient, it is also possible to auxiliary containing pharmaceutically acceptable
Material.Preferably, pharmaceutical composition of the present invention is prepared as granule according to conventional fabrication process.
The pharmacological action of Chinese medicine of the present invention is as follows:
Carnis Canitis, sweet in the mouth, warm in nature, salty, return spleen, stomach, kidney channel;There are warming and invigorating the spleen and stomach, reinforcing the kidney and supporting YANG, strong strength, the effect of arteries and veins of enriching blood, use
In diseases such as the chills and pain of the waist and kness caused by insufficiency of kidney-YANG, clear urine in large amounts, frequent micturition, edema, deafness, the enuresis.
Ootheca Mantidis, nature and flavor are sweet, salty, flat；Return liver, kidney channel；Supplementing the kidney to control the nocturnal, reducing urination is the most turbid.For emission and spermatorrhea, the enuresis is urinated
Frequently, urine nebulousurine.
Fructus Tritici Levis: sweet in the mouth, cool in nature；GUIXIN warp；Control hectic fever due to YIN-deficiency consumptive fever, only spontaneous sweating；" modern Practical Chinese medicinal " thinks floating little
Wheat can reinforcing the heart, only tired, heat extraction, arresting sweating, diuresis.
The Radix Paeoniae Alba, cool in nature, bitter in the mouth acid, it is slightly cold, there is the effects such as blood-supplementing blood-nourishing, suppressing liver-YANG, easing the affected liver to relieve pain, astringing YIN to stop sweating,
Fructus Alpiniae Oxyphyllae, nature and flavor are pungent, temperature；Entering spleen, kidney channel, temperature compensation is astringent or styptic treatment for spontaneous sweating, warm spleen antidiarrheal, astringency inducing saliva, the kidney warming controlling nocturnal emission with astringent drugs reducing urination.
Teata glycinis, sweet in the mouth is put down.The detumescence therapeutic method to keep the adverse QI flowing downwards, lung moistening is scorching, activating blood and promoting diuresis, wind expelling stagnation removing, blood-enriching tranquillizing, improving eyesight are good for
Spleen, the kidney invigorating tonifying YIN, the effect of removing toxic substances；For: lumbocrural pain, kidney deficiency and bodily weakness, insufficiency of the spleen chronic diarrhea, anemia, breathe hard, dyspepsia, dream
Lose spermatorrhea, urine urgency-frequency, nebulousurine leukorrhagia.
Fructus Schisandrae Chinensis: sour, warm.Return lung, the heart, kidney channel.Restrain astringent or styptic treatment for spontaneous sweating, supplementing QI for promoting the production of body fluid, mind tranquilizing and the heart calming.Cure mainly cough dyspnea due to deficiency, dream
Losing spermatorrhea, urinate the quite enuresis, incessant chronic diarrhea, spontaneous sweating, Tianjin wound is thirsty, palpitation and insomnia etc..
Medicine of the present invention, to adjust reinforcing the heart gas, training unit astringent or styptic treatment for spontaneous sweating as Therapeutic Principle, Carnis Canitis warming and invigorating the spleen and stomach, reinforcing the kidney and supporting YANG, benefit in side
Blood vessels, Fructus Alpiniae Oxyphyllae the kidney warming controlling nocturnal emission with astringent drugs reducing urination, both are monarch drug；Fructus Tritici Levis reinforcing the heart, only tired, Radix Paeoniae Alba blood-supplementing blood-nourishing, both be both in harmonious proportion monarch
The scorching monarch drug orderliness heart kidney of cooperation again of medicine is ministerial drug；Ootheca Mantidis supplementing the kidney to control the nocturnal, astringent therapy are only lost, and teata glycinis blood-enriching tranquillizing is assistant
Medicine, Fructus Schisandrae Chinensis sour in the mouth, have receipts antiperspirant arresting seminal emission, priming return through effect.Medicament composing prescription of the present invention is reasonable, and determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs can be effective
Cure bed-wetting particularly heart kidney deficiency bed-wetting disease.Verify by clinic application, determined curative effect, mild in medicine property and, not
Toxic and side effects and serious adverse reaction occur, safety coefficient is high, and clinical observation total effective rate reaches more than 93%, the present invention simultaneously
The medicine medication of preparation is convenient, improves the compliance of infant.
The present inventor has done clinical efficacy contrast with the medicine of the present invention with contracting spring capsule (traditional Chinese medicines quasi-word Z199901039)
Experiment, is summarized as follows:
1, physical data: select hospital ward and outpatient clinic meet bed-wetting (heart kidney two deficiency syndrome) diagnostic criteria suffer from 88
Example.Random packet, the method for parallel control is used to study.
In included in the object of observation, treatment group: 44 examples, male 25 examples, female 19 example, age 5-10 year, course of disease 1-4, with
Spina bifida occulta 6 example.Matched group: 44 examples, male 24 examples, female 20 example, in age 6-10 year, course of disease 1-4, with spina bifida occulta 5
Example.The physical data such as two groups of ages, course of disease situations compare, and all have comparability (P ＞ 0 .05).
2, diagnosis basis:
(1) bed-wetting tcm diagnosis standard
A () sleep is relatively deep, be difficult to wake up up, wet the bed every night or every several days, the most then a nocturia bed is for several times；
B () age of onset is more than 5 one full year of life；
C () urine is conventional and urine cultivates discovery how without exception；
D () x-ray takes the photograph sheet inspection, part infant can be found to have spina bifida occulta, urinary system x-ray radiography its textural anomaly visible.
2) TCM syndrome diagnostic criteria:
Syndrome of qi deficiency of spleen and lung: sleep the middle enuresis, frequent micturition and measure many, lusterless complexion, spiritlessness and weakness, inappetence, big loose stool is thin.Tongue is inclined
Light, moderate pulse is thin.
3) Western medicine diagnose standard:
The primary enuresis diagnostic criteria announced with reference to international Children's Urine control association (ICCS) in 1998:
Under (a) sleep state urine drains in bed, patient, without uriesthesia, generally will not wake up because urine is wet, have
Genetic predisposition；
(b) age of onset 5 years old, weekly enuresis number of times ＞ 2 times；
C there is the enuresis in () after birth, does not has continuous more than 6 months do not wet the bed the phase；
D () is got rid of common, may to cause bed-wetting organic disease such as urinary tract infection, Urinary malformation, diabetes, urine and is collapsed
Disease and neurogenic bladder, cerebral hypoplasia etc..
3, inclusive criteria:
A () meets bed-wetting diagnostic criteria and syndrome of qi deficiency of spleen and lung TCM syndrome diagnostic criteria.
(b) age between 5-10 year, male or female.
C () course of disease continues more than 3 months persons.
(d) signature " Informed Consent Form " person.
4, exclusion standard:
A () does not signs " Informed Consent Form " person.
(b) secondary enuresis patient.
(c) long-term taking (acceptance) other medicines (method for the treatment of) and the person that takes Comprehensive Treatment.
D () age is person's (not including 10 years old) more than 10 years old.
E () merges the serious disease persons such as the heart, brain, liver, kidney and hemopoietic system, psychotic.
F () routine urinalysis and urine cultivate detection abnormal.
G () is known maybe may be to trial drug and component allergy sufferers thereof.
5, reject and come off standard:
A () case is selected after, find not meet inclusive criteria or meet exclusion standard person.
B there is serious adverse events in (), judge to stop this case clinical trial person according to doctor.
C () case is selected after, data is the most entirely or by specifying medication person.
D, in () process of the test, experimenter's compliance is poor, affect the treatment estimator.
6, usage and dosage:
Treatment group: take Drug therapy of the present invention, granule prepared by Example 1, every bag of amount 10g Han crude drug, each 1 bag,
2 times on the one.
Matched group: contracting spring capsule (traditional Chinese medicines quasi-word Z199901039), oral, one time 3, three times a day.
Be used in conjunction 10 days was 1 course for the treatment of.After 3 courses for the treatment of terminate, follow up a case by regular visits to 2 weeks and carry out efficacy evaluation.
7, efficacy evaluation:
The efficacy assessment standard announced with reference to international Children's Urine control association (ICCS) in 1998:
The enuresis time weekly before enuresis number of times slip=(before treatment weekly after enuresis number of times-treatment weekly enuresis number of times)/treatment
Number × 100%.
(1) reaction (healing) completely: after treatment is finished in two weeks, enuresis frequency reduces more than 90%.
(2) partial reaction (improvement): after treatment is finished in two weeks, enuresis frequency reduces 50%-90%.
(3) reactionless (invalid): after treatment is finished in two weeks, enuresis frequency reduces less than 50%.
8, therapeutic effect:
Without rejecting and the case that comes off in therapeutic process, all complete clinical observation.
After two groups of patient treatment 3 courses for the treatment of, total effects compares, and treatment group cure rate is 45 .45%, and matched group is 36.36%,
Cure rate compares, P value equal ＜ 0 .05, has significant difference；Total effective rate treatment group is 93 .1%, and matched group is 79
.5%, total effective rate compares, P value equal ＜ 0 .05, has significant difference.
Table 1. treatment group and the comparitive study of matched group
| Group | Cure | Take a turn for the better | Invalid | Total effective rate |
| Treatment group | 20 | 21 | 3 | 93 .1% |
| Matched group | 16 | 19 | 9 | 79 .5% |
Routine blood test, routine urinalysis, electrocardiogram change without exception before and after treatment group patient treatment, in therapeutic process, vital sign is steady
And without the untoward reaction such as nausea and vomiting, allergy, illustrate that the clinical application of we is safe and reliable.Therapeutic outcome shows treatment
Group cure rate and effective percentage are substantially better than matched group, have significant difference.
Thus explanation use Drug therapy bed-wetting of the present invention is particularly treated and is belonged to heart kidney deficiency children's something lost
Urine, achieves significant curative effect, and clinical practice is safe and reliable, is worth research and popularization and application further.
By clinical trial, after two groups of patient treatment 3 courses for the treatment of, total effects compares, and treatment group cure rate is 45.45%,
Matched group is 36.36%, and cure rate compares, P value equal ＜ 0 .05, has significant difference；Total effective rate treatment group is 93 .1%,
Matched group is 79.5%, and total effective rate compares, P value equal ＜ 0 .05, has significant difference.
In safety evaluatio, before and after treatment group patient treatment, the change without exception such as routine blood test, routine urinalysis, electrocardiogram, controls
During treatment, vital sign is steadily and without the untoward reaction such as nausea and vomiting, allergy.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to implement in detail below
Example.Within the scope of the invention or without departing from present disclosure, spirit and scope, change that the present invention is carried out,
Combination or replacement, will be apparent to the person skilled in the art, and be included within the scope of the present invention.
Embodiment one
The each raw material of the present invention is weighed: Carnis Canitis 12 parts, Ootheca Mantidis 4 parts, Fructus Tritici Levis 8 parts, the Radix Paeoniae Alba 4 parts, teata glycinis 8 by following weight portion
Part, Fructus Alpiniae Oxyphyllae 4 parts, Fructus Schisandrae Chinensis 4 parts.
Preparation technology is as follows: by the raw material Carnis Canitis of above-mentioned weight portion, Ootheca Mantidis, Fructus Tritici Levis, the Radix Paeoniae Alba, Semen sojae atricolor, Fructus Alpiniae Oxyphyllae, and five
After taste is pulverized, add the water of 10 times amount of medical material gross weight, after soaking 30 minutes, decoct 2 times, 80 minutes for the first time, for the second time
40 minutes, filter, and the filtrate reduced in volume after merging to 75 DEG C time, its relative density be the thick paste of 1 .10-1 .15 i.e.
?.Those skilled in the art can be the most directly used as medicine use or add adjuvant conventional formulation technique and prepare oral
The oral formulations that liquid, granule, electuary, capsule or powder etc. are conventional.
When using medicine composite for curing infantile enuresis of the present invention, take prepared oral liquid, every bottle of amount Han crude drug
10g, each 1 bottle, 2 times on the one.Take prepared granule, electuary or powder, every bag of g Han crude drug amount 10, each 1 bag, one
Day 2 times.
Claims (6)
1. the medicine treating heart kidney deficiency infantile enuresis, it is characterised in that: it is by the crude drug system of following weight portion
: Carnis Canitis 6-18 part, Ootheca Mantidis 2-6 part, Fructus Tritici Levis 4-12 part, Radix Paeoniae Alba 2-6 part, Semen sojae atricolor 4-12 part, Fructus Alpiniae Oxyphyllae 2-6 part, the five tastes
Sub-2-6 part.
2. the medicine treating heart kidney deficiency infantile enuresis as claimed in claim 1, it is characterised in that: it is by following weight
The crude drug of part prepares: Carnis Canitis 12 parts, Ootheca Mantidis 4 parts, Fructus Tritici Levis 8 parts, the Radix Paeoniae Alba 4 parts, 8 parts of Semen sojae atricolor, Fructus Alpiniae Oxyphyllae 4 parts, Fructus Schisandrae Chinensis 4
Part.
3. the medicine treating heart kidney deficiency infantile enuresis as claimed in claim 1 or 2, it is characterised in that: described medicine
Compositions is oral formulations.
4. the medicine treating heart kidney deficiency infantile enuresis as claimed in claim 3, it is characterised in that: described oral formulations
For oral liquid, pill, granule, capsule or powder.
5. the medicine treating heart kidney deficiency infantile enuresis as claimed in claim 4, it is characterised in that described oral formulations
For granule.
6. the method preparing the medicine for the treatment of heart kidney deficiency infantile enuresis as claimed in claim 1 or 2, its feature
Be, comprise the steps: by the crude drug Carnis Canitis of weight portion described in claim 1 or 2, Ootheca Mantidis, Fructus Tritici Levis, the Radix Paeoniae Alba,
Semen sojae atricolor, Fructus Alpiniae Oxyphyllae, after Fructus Schisandrae Chinensis is pulverized, add the water of 10 times amount of medical material gross weight, after soaking 30 minutes, decocts 2 times, for the first time
60-90 minute, 30-60 minute for the second time, filter, and will merge after filtrate reduced in volume to 75 DEG C time, its relative density is
The thick paste of 1 .10-1 .15 and get final product；Add the adjuvant accepted on pharmaceutics and required preparation is produced in conventional fashion into.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610680014.1A CN106138947A (en) | 2016-08-18 | 2016-08-18 | A kind of medicine treating heart kidney deficiency infantile enuresis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610680014.1A CN106138947A (en) | 2016-08-18 | 2016-08-18 | A kind of medicine treating heart kidney deficiency infantile enuresis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138947A true CN106138947A (en) | 2016-11-23 |
Family
ID=57330401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610680014.1A Pending CN106138947A (en) | 2016-08-18 | 2016-08-18 | A kind of medicine treating heart kidney deficiency infantile enuresis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138947A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101036765A (en) * | 2007-04-05 | 2007-09-19 | 史爱国 | Externally used medicine for treating anischuria and its preparation method |
| CN101152514A (en) * | 2007-09-24 | 2008-04-02 | 范玉堂 | Traditional Chinese medicine for treating customary children's urorrhea |
| CN103120779A (en) * | 2012-12-17 | 2013-05-29 | 李承平 | Fructus alpiniae oxyphyllae tablet for treating enuresis |
| CN104435614A (en) * | 2014-12-24 | 2015-03-25 | 周连才 | Pharmaceutical composition for treating infantile enuresis |
| CN104547822A (en) * | 2013-10-23 | 2015-04-29 | 孙丰卿 | Traditional Chinese medicinal composition for treating child enuresis and preparation method of preparations thereof |
-
2016
- 2016-08-18 CN CN201610680014.1A patent/CN106138947A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101036765A (en) * | 2007-04-05 | 2007-09-19 | 史爱国 | Externally used medicine for treating anischuria and its preparation method |
| CN101152514A (en) * | 2007-09-24 | 2008-04-02 | 范玉堂 | Traditional Chinese medicine for treating customary children's urorrhea |
| CN103120779A (en) * | 2012-12-17 | 2013-05-29 | 李承平 | Fructus alpiniae oxyphyllae tablet for treating enuresis |
| CN104547822A (en) * | 2013-10-23 | 2015-04-29 | 孙丰卿 | Traditional Chinese medicinal composition for treating child enuresis and preparation method of preparations thereof |
| CN104435614A (en) * | 2014-12-24 | 2015-03-25 | 周连才 | Pharmaceutical composition for treating infantile enuresis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1706436A (en) | Tranquilizing soporific Chinese medicine | |
| CN108042699A (en) | A kind of pharmaceutical composition for treating insomnia, preparation and preparation method thereof | |
| CN102526474A (en) | Chinese medicine composition for treating neurasthenia | |
| CN106266177A (en) | A kind of Chinese patent medicine of relieving mental strain and helping sleep | |
| CN101062356B (en) | Chinese traditional medicine for treating children's enuresis | |
| CN104474341B (en) | A kind of pharmaceutical composition for the treatment of hyperkinetic syndrome | |
| CN104274725B (en) | It is a kind of to treat depressed Chinese medicine composition for merging insomnia and preparation method and application | |
| CN104435614B (en) | A kind of pharmaceutical composition for the treatment of bed-wetting | |
| CN106924388B (en) | A kind of pharmaceutical composition for treating insomnia and preparation method thereof, preparation and application | |
| CN104435519A (en) | Pharmaceutical composition for treating primary dysmenorrhea | |
| CN101810787A (en) | Chinese medicinal composition for treating dysphoria and preparation method thereof | |
| CN102908396B (en) | Chinese medicinal composition for promoting sleeping and preparation method thereof | |
| CN105456818A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition | |
| CN105327092B (en) | It is a kind of to treat the Chinese medicine composition and its application that cervical is had a sleepless night | |
| CN104336428A (en) | Health care product conducive to sleep | |
| CN107737319A (en) | Improve Chinese medicine preparation of sleep quality and preparation method thereof | |
| CN107519297A (en) | Treat the preparation and preparation method of Qi dysfunction in blood control caused thrombocytopenic purpura | |
| CN106138947A (en) | A kind of medicine treating heart kidney deficiency infantile enuresis and preparation method thereof | |
| CN102441103B (en) | Medicine for treating insomnia | |
| CN101804184B (en) | Traditional Chinese medicine composition for treating chest distress and preparation method thereof | |
| CN104352867A (en) | Traditional Chinese medicine composition for treating gestational depression | |
| CN100998744A (en) | Chinese patent drug for treating infantile hyperkinetic syndrome | |
| CN104491588A (en) | Health-care tea used for insomnia | |
| CN116688046B (en) | Traditional Chinese medicine composition for treating children enuresis due to spleen-lung qi deficiency, and preparation method and application thereof | |
| CN115120687B (en) | Traditional Chinese medicine composition for treating children enuresis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161123 |